-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 13th, Livzon submitted a clinical application for a new class of 3.
Picture 1: Livzon's newly declared products
Source: CDE official website
Smeglutide is a human glucagon-like peptide-1 (GLP-1) analog, which promotes insulin secretion and inhibits glucagon secretion through a glucose concentration-dependent mechanism, which can increase the blood glucose level of patients with type 2 diabetes.
Novo Nordisk has developed injection preparations (Ozempic) and oral preparations (Rybelsus) for smeglutide.
Figure 2: The situation of domestic pharmaceutical companies that have submitted clinical applications earlier
Source: Meinenet MED2.
Zhuhai United Laboratories and Hangzhou Jiuyuan Genetic Engineering submitted clinical applications for Class 3.
Recently, Livzon’s biopharmaceuticals under development have good news.
Figure 3: Merck Gonafen's sales in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
According to data from Mi Nei.
Source: CDE official website, Minet database
The review data statistics are as of September 14.